Market Overview

BMO: Aeglea Has A Potentially Market-Conquering Arginase Deficiency Candidate, Oncology Opportunity

Share:
BMO: Aeglea Has A Potentially Market-Conquering Arginase Deficiency Candidate, Oncology Opportunity
Related
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs
The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise

Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) hasn’t received much attention in its two years on the market, but on Thursday it caught the eye of its fourth analyst and fourth bull.

The Rating

BMO Capital Markets analyst Matthew Luchini initiated coverage of Aeglea with an Outperform rating and $21 price target.

The Thesis

BMO expects Aeglea’s pegzilarginase to transform the treatment of Arginase I Deficiency (ARG1-D), which currently lacks effective therapies.

“Pegzilarginase could be the standard of care in ARG1-D, a nearly $400-million unadjusted peak sales opportunity,” Luchini said in a note. The analyst forecast that Aeglea will capture 90 percent of the market within five to nine years. 

The program appears to be derisked by recent Phase 1 and 2 trial data linking clinically relevant improvements to arginine reduction, Luchini said.

BMO expects to see similar results among more patients in the third quarter, paving the way for Phase 3 trials in 2019 and likely approval in 2021.

Notably, the candidate is seen to have potential in oncology, in which there are two ongoing studies with data expected in the fourth quarter.

“We believe the rationale for development in cancer is solid given the large proportion of tumors with arginine-dependence biomarkers across a range of cancer subtypes,” Luchini said. 

He anticipates peak sales exceeding $1 billion in melanoma and small-cell lung cancer alone. 

Price Action

Shares peaked 9 percent on the BMO rating but had faded back to $10.24 by the time of publication Thursday. 

Related Links:

Flex Pharma Shares Plunge After Biotech Ends 2 Clinical Trials, Announces 60% Workforce Cut

Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate

Latest Ratings for AGLE

DateFirmActionFromTo
Sep 2018Wells FargoDowngradesOutperformMarket Perform
Jun 2018BMO CapitalInitiates Coverage OnOutperform
Apr 2018Evercore ISI GroupInitiates Coverage OnOutperform

View More Analyst Ratings for AGLE
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Matthew LuchiniAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (AGLE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TEAMKeyBancUpgrades89.0
VIABImperial CapitalUpgrades29.0
AMDBarclaysUpgrades25.0
CDNSJP MorganUpgrades51.0
EBAYRBC CapitalDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

ECB Quick Analysis: Doves 3, Hawks 1 - Draghi Drags The EUR/USD Down

Fifth Third Is Worth A Premium Despite Sluggish Loan Growth, Argus Says In Bullish Initiation